MOHAMMAD QASAYMEH
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology with Special Qualifications in Child Neurology AMHERST, NY NPI 1528074341
Browse related groups: Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology with Special Qualifications in Child Neurology NY ABBVIE INC. All categories
General Payments — all program years on this page
$40,885.24
- Category: General Payments
- Program years: PY2018–2024
- Record count: 720
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $2,355.53 across 103 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,355.53 | 103 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $675.73 | 28 |
| UCB, Inc. | $376.35 | 18 |
| PFIZER INC. | $214.51 | 14 |
| LivaNova USA, Inc. | $211.32 | 10 |
| Alexion Pharmaceuticals, Inc. | $146.70 | 2 |
| Pyros Pharmaceuticals, Inc. | $112.00 | 1 |
| CATALYST PHARMACEUTICALS, INC. | $86.67 | 4 |
| ACADIA Pharmaceuticals Inc | $85.12 | 4 |
| Corium, Inc. | $62.48 | 2 |
| JAZZ PHARMACEUTICALS INC. | $56.41 | 3 |
| SK Life Science, Inc. | $55.80 | 2 |
| Teva Pharmaceuticals USA, Inc. | $33.67 | 2 |
| GE HEALTHCARE | $27.76 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.20 | 1 |
| Biogen, Inc. | $23.04 | 1 |
| Grifols USA, LLC | $22.76 | 1 |
| SpringWorks Therapeutics, Inc. | $21.97 | 1 |
| SCILEX PHARMACEUTICALS INC. | $21.26 | 1 |
| Lilly USA, LLC | $19.29 | 1 |
| Neurocrine BioSciences, Inc. | $18.08 | 1 |
| Merck Sharp & Dohme Corporation | $17.17 | 1 |
| Acerta Pharma LLC | $16.50 | 1 |
| Neurelis, Inc. | $14.00 | 1 |
| Alnylam Pharmaceuticals Inc. | $13.74 | 1 |
By program year
Records — PY2024 (103)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.